Literature DB >> 31950651

Haemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test.

Nicola R Pugliese1, Matteo Mazzola1, Iacopo Fabiani2, Luna Gargani3, Nicolò De Biase1, Roberto Pedrinelli2, Andrea Natali1, Frank L Dini2.   

Abstract

AIM: We combined cardiopulmonary exercise test (CPET) and exercise stress echocardiography (ESE) to identify early haemodynamic and metabolic alterations in patients with hypertension (HT) with and without heart failure with preserved ejection fraction (HFpEF). METHODS AND
RESULTS: Fifty stable HFpEF-HT outpatients (mean age 68 ± 14 years) on optimal medical therapy, 63 well-controlled HT subjects (mean age 63 ± 11 years) and 32 age and sex-matched healthy controls (mean age 59 ± 15 years) underwent a symptom-limited graded ramp bicycle CPET-ESE. The acquisition protocol included left ventricular cardiac output, global longitudinal strain, E/e', peak oxygen consumption (VO2 ), non-invasive arterial-venous oxygen content difference (AVO2 diff) and lung ultrasound B-lines. There was a decline in peak VO2 from controls (24.4 ± 3 mL/min/kg) to HFpEF-HT (15.2 ± 2 mL/min/kg), passing through HT (18.7 ± 2 mL/min/kg; P < 0.0001). HFpEF-HT displayed a lower peak cardiac output (9.8 ± 0.9 L/min) compared to HT (12.6 ± 1.0 L/min; P = 0.02) and controls (13.3 ± 1.0 L/min; P = 0.01). Peak AVO2 diff was reduced in HFpEF-HT and HT (13.3 ± 2 and 13.5 ± 2 mL/dL vs. controls: 16.9 ± 2 mL/dL; P < 0.0001). A different left ventricular contractility was observed among groups, expressed as low-load global longitudinal strain (-16.8 ± 5% in HFpEF-HT, -18.2 ± 3% in HT, and 20.9 ± 3% in controls; P < 0.0001), and distribution of E/e' and B-lines [HFpEF-HT: 13.7 ± 3 and 16, interquartile range (IQR) 10-22; HT: 9.5 ± 2 and 8, IQR 4-10; controls: 6.2 ± 2 and 0, IQR 0-2; P < 0.0001].
CONCLUSIONS: Reduced peak VO2 values in HT with and without HFpEF may be the result of decreased AVO2 diff. CPET-ESE can also identify mild signs of left ventricular systo-diastolic dysfunction and pulmonary congestion, promoting advances in personalized therapy.
© 2020 European Society of Cardiology.

Entities:  

Keywords:  Arterial hypertension; Cardiopulmonary exercise test; Exercise stress echocardiography; Heart failure with preserved ejection fraction

Mesh:

Year:  2020        PMID: 31950651     DOI: 10.1002/ejhf.1739

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  9 in total

1.  Diabetes Is the Strongest Predictor of Limited Exercise Capacity in Chronic Heart Failure and Preserved Ejection Fraction (HFpEF).

Authors:  Venera Berisha-Muharremi; Michael Y Henein; Frank L Dini; Edmond Haliti; Ibadete Bytyçi; Pranvera Ibrahimi; Afrim Poniku; Arlind Batalli; Rina Tafarshiku; Shpend Elezi; Gani Bajraktari
Journal:  Front Cardiovasc Med       Date:  2022-05-26

2.  Evaluating Impact of Pulse Pressure on Indexes of Myocardial Work by Speckle-Tracking Echocardiography in Normotensive, Prehypertensive and Newly Diagnosed Hypertensive Patients.

Authors:  Zheng Qin; Dawei Liu; Xiaojun You; Qin Duan; Yu Zhao
Journal:  Int J Gen Med       Date:  2022-02-22

Review 3.  A year in heart failure: an update of recent findings.

Authors:  Lorenzo Stretti; Dauphine Zippo; Andrew J S Coats; Markus S Anker; Stephan von Haehling; Marco Metra; Daniela Tomasoni
Journal:  ESC Heart Fail       Date:  2021-12-16

4.  Renin Feedback Is an Independent Predictor of Outcome in HFpEF.

Authors:  Christina Binder; Marko Poglitsch; Franz Duca; René Rettl; Theresa Marie Dachs; Daniel Dalos; Lore Schrutka; Benjamin Seirer; Luciana Camuz Ligios; Christophe Capelle; Roza Badr Eslam; Hong Qin; Christian Hengstenberg; Diana Bonderman
Journal:  J Pers Med       Date:  2021-05-03

5.  Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach.

Authors:  Lorenzo Nesti; Nicola Riccardo Pugliese; Paolo Sciuto; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2020-09-05       Impact factor: 9.951

6.  Right Heart Pulmonary Circulation Unit Response to Exercise in Patients with Controlled Systemic Arterial Hypertension: Insights from the RIGHT Heart International NETwork (RIGHT-NET).

Authors:  Olga Vriz; Paolo Palatini; Lawrence Rudski; Paolo Frumento; Jarosław D Kasprzak; Francesco Ferrara; Rosangela Cocchia; Luna Gargani; Karina Wierzbowska-Drabik; Valentina Capone; Brigida Ranieri; Andrea Salzano; Anna Agnese Stanziola; Alberto Maria Marra; Roberto Annunziata; Salvatore Chianese; Salvatore Rega; Teresa Saltalamacchia; Renato Maramaldi; Chiara Sepe; Giuseppe Limongelli; Filippo Cademartiri; Antonello D'Andrea; Michele D'Alto; Raffaele Izzo; Nicola Ferrara; Ciro Mauro; Antonio Cittadini; Grünig Ekkehard; Marco Guazzi; Eduardo Bossone
Journal:  J Clin Med       Date:  2022-01-17       Impact factor: 4.241

Review 7.  Arterial Hypertension and Cardiopulmonary Function: The Value of a Combined Cardiopulmonary and Echocardiography Stress Test.

Authors:  Lavinia Del Punta; Nicolò De Biase; Nicola Riccardo Pugliese; Stefano Masi; Alessio Balletti; Francesco Filidei; Alessandra Pieroni; Silvia Armenia; Alessandro Mengozzi; Matteo Mazzola; Valerio Di Fiore; Frank Lloyd Dini; Javier Rosada; Agostino Virdis; Stefano Taddei
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-02-02

8.  Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes.

Authors:  Lorenzo Nesti; Nicola Riccardo Pugliese; Paolo Sciuto; Nicolò De Biase; Matteo Mazzola; Iacopo Fabiani; Domenico Trico; Stefano Masi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-06-22       Impact factor: 9.951

9.  Combined use of stress echocardiography and cardiopulmonary exercise testing to assess exercise intolerance in patients treated for acute myocardial infarction.

Authors:  Krzysztof Smarz; Tomasz Jaxa-Chamiec; Beata Zaborska; Maciej Tysarowski; Andrzej Budaj
Journal:  PLoS One       Date:  2021-08-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.